Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InspireMD, a medical device company, has announced the enrollment of the first three patients in its study of MGuard coronary stent in acute myocardial infarction.
Subscribe to our email newsletter
The Guard Study (MGuard) in acute myocardial infarction study is designed to evaluate the safety and efficacy of MGuard in patients suffering from ST-segment elevation myocardial infarction. The first three patients were implanted successfully with the MGuard coronary stent, in the Jagiellonian University Clinic, in Krakow, Poland.
The Guard study is a prospective, multi center study, designed to confirm the feasibility, efficacy and safety of MGuard in acute myocardial infarction patients. The Guards study will include 60 patients, and its primary endpoints are complete resolution of ST-segment elevation and restoration of flow through the occluded artery.
Eli Bar, CTO and vice president of R&D at InspireMD, said: “MGuard is designed to provide a comprehensive solution to the embolization threat, during and post procedure. We are confident that the Guard Study will confirm what we have experienced so far in cath labs around the world that the product performs well and delivers extra safety to acute myocardial infarction patients.”